wave life sciences news

Wave Life Sciences

WAVE Life Sciences Ltd (WVE) Q3 2024: Everything You Need to Know Ahead of Earnings

WAVE Life Sciences Ltd (NASDAQ:WVE) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $16.95 million, and the earnings are expected to come in at -$0.

Zacks.com on MSN · 3h

Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.

Seeking Alpha · 1h

Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded and webcast. I'll now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three ...

MarketBeat on MSN25d

Wave Life Sciences Rockets 70% on Historic RNA Editing Success

For the most recent quarter, Wave Life Sciences reported -$0.25 earnings per share (EPS), missing the consensus ...

B. Riley Raises Wave Life Sciences (NASDAQ:WVE) Price Target to $22.00

Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective increased by research analysts at B. Riley from $19.00 to $22.00 in a note issued to investors on Monday, Benzinga reports.

Wave Life Sciences treatment of Huntington’s disease gets FDA orphan designation

According to a post on the FDA’s website, Wave Life Sciences (WVE)’ treatment of Huntington’s disease received orphan ...

RNA editing promises to go where DNA editing can’t

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for ...

ETF Daily News25d

Wave Life Sciences (NASDAQ:WVE) PT Raised to $22.00

Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective upped by Leerink Partners from $20.00 to $22.00 in a note issued to investors on Wednesday, Benzinga reports.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results